ACTA VIROLOGICA, a key journal in the field of virology and infectious diseases, is published by FRONTIERS MEDIA SA in Slovakia, serving the global scientific community with groundbreaking research since its inception in 1957. This esteemed journal, identified by ISSN 0001-723X and E-ISSN 1336-2305, provides a platform for rigorous peer-reviewed articles that contribute significantly to our understanding of viral pathogens and their implications in medicine. Positioned within the Q3 category for both Infectious Diseases and Miscellaneous Medicine, and a Q4 category for Virology in 2023, ACTA VIROLOGICA offers crucial insights into the evolving landscape of virology research. With its robust accessibility options, this journal appeals to a diverse readership, including researchers, healthcare professionals, and students, fostering a collaborative environment to advance the field of virology. The editorial objective is to enhance the catalog of knowledge pertaining to viruses, promoting innovative approaches in prevention, diagnostics, and treatment. Located at AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE CH-1015, SWITZERLAND, ACTA VIROLOGICA continues to be a vital resource in the collective efforts to combat viral disease challenges.

Virology, published by Academic Press Inc. Elsevier Science, is a prominent journal dedicated to advancing the knowledge and understanding of viral biology and pathogenesis since its inception in 1955. With a distinguished impact factor and recognized as a Q2 journal in the field of Virology for 2023, it ranks 38 out of 80 in the Scopus database for Immunology and Microbiology, placing it in the 53rd percentile among similar publications. This esteemed journal provides a platform for groundbreaking research, critical reviews, and comprehensive studies that contribute to our global understanding of viruses and their impact on health and disease. Although currently not an open-access journal, it remains accessible to a wide audience of researchers, professionals, and students who are keen to explore the latest advancements in virological research. The journal's scope encompasses a diverse range of topics, ensuring that it serves as an essential resource for anyone engaged in virology and related biomedical fields.

Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.

ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, published by DE GRUYTER POLAND SP Z O O, stands as a pivotal journal in the field of immunology, contributing significantly to the advancement of knowledge and therapy in this crucial area of medicine since its inception in 1954. With an ISSN of 0004-069X and an E-ISSN of 1661-4917, the journal operates out of Switzerland, catering to an international audience of researchers, practitioners, and students. As reflected in its Scopus rankings, the journal is positioned within the third quartile in both Immunology and Allergy (Q3) and holds a commendable second quartile in Medicine (miscellaneous) (Q2), indicating its respectable influence within the academic community. The journal publishes original research, reviews, and clinical studies, offering a platform for exploring cutting-edge developments in immunological therapies and experimental methods. Although not currently an open-access journal, it continues to thrive as a valuable resource, reflecting a commitment to disseminating high-quality research and fostering academic discourse in the field. Researchers and professionals alike will find ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS an essential reference source for the latest advancements in immunological research and clinical applications.

VIROLOGIE is a prominent international journal dedicated to advancing the field of virology and infectious diseases, published by John Libbey Eurotext Ltd. Since its inception in 1997, this journal has provided a platform for researchers and professionals to disseminate their findings on various aspects of virology, including the pathogenesis, epidemiology, and treatment of viral infections. Despite its current ranking in Q4 for both Infectious Diseases and Virology categories, the journal remains a valuable resource for emerging research and novel insights. The ISSN for the journal is 1267-8694, and it is based in France. VIROLOGIE is committed to upholding rigorous academic standards and fosters an inclusive scholarly community, making it an essential read for those pursuing knowledge and advancements in the ever-evolving landscape of virology. While the journal does not currently offer open access options, it continues to contribute significantly to the global discourse on viral research through its diverse range of published studies.

The Journal of Clinical Virology Plus, published by Elsevier, is an essential resource for researchers and professionals in the fields of virology and infectious diseases. Launched in 2021, this journal aims to bridge the gap between clinical research and application, fostering a deeper understanding of viral pathogenesis, diagnostics, and therapeutic strategies. With an ISSN of 2667-0380, this open-access journal brings cutting-edge findings to the global scientific community, facilitating the rapid dissemination of knowledge critical for advancing public health. Positioned in the Q3 category for both Infectious Diseases and Virology in 2023, its ranking reflects its growing influence and relevance in the academic landscape. The journal strives to support innovative research, collaborative studies, and comprehensive reviews that address contemporary challenges in clinical virology. As it converges through the years from 2021 to 2024, Journal of Clinical Virology Plus aims to be a central hub for vital discussions and breakthroughs in this dynamic field.

INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.

AIDS RESEARCH AND HUMAN RETROVIRUSES, published by Mary Ann Liebert, Inc., is a pivotal journal dedicated to advancing the field of HIV research and the broader spectrum of human retroviruses. With an ISSN of 0889-2229 and an E-ISSN of 1931-8405, this journal has been in continuous publication since 1987 and is respected in the academic community for its rigorous peer-reviewed articles. As a Q3 ranked journal in Immunology, Infectious Diseases, and Virology as of 2023, it plays a crucial role in disseminating cutting-edge research, theoretical advancements, and clinical insights that contribute significantly to the understanding and treatment of HIV and related disorders. The journal's objective is to foster collaboration among researchers, healthcare professionals, and educators by providing a platform for the exchange of innovative ideas and findings. Although not an open-access journal, its compelling content ensures that it remains a primary resource for those in the academic and medical communities tackling the challenges posed by retroviral infections. With a commitment to excellence and relevance, AIDS RESEARCH AND HUMAN RETROVIRUSES continues to shape the future of research in this critical area.

ANTIVIRAL RESEARCH, published by Elsevier, stands at the forefront of the study of antiviral agents and therapy, with a dedicated focus on advancing the understanding of viral infections and their mechanisms. The journal is recognized within the top tier of academic publications, belonging to the prestigious Q1 category in both Pharmacology and Virology as of 2023, ranking 12th out of 313 in Pharmacology and 11th out of 80 in Virology according to Scopus metrics, reflecting its significant impact in the field. With a long-standing history since its inception in 1959, it continues to serve as an essential platform for researchers and health professionals alike, sharing critical findings that drive innovation in antiviral therapeutics. Although it does not currently offer open access options, the journal’s rigorous peer-review process ensures that every published article meets high academic standards, providing invaluable insights for those dedicated to enhancing public health through virology research.

Journal of Virological Methods, published by Elsevier, is a prominent peer-reviewed journal dedicated to advancing the methodologies employed in virology research. Since its inception in 1980, this esteemed journal has become a vital resource for researchers, professionals, and students focused on the intricate study of viruses and viral-related diseases. With a current ISSN of 0166-0934 and an E-ISSN of 1879-0984, this journal strives to present innovative techniques and tools that enhance our understanding of virology. Designed for a global audience, it operates in a rigorous academic environment, as reflected by its 2023 Scopus ranking of #40 in the Virology category and its Q3 quartile placement. The journal is committed to fostering open dialogue and collaboration within the scientific community, ultimately contributing to the development of novel strategies and interventions against viral infections. By offering comprehensive insights into virological methodologies, the Journal of Virological Methods continuously serves as a cornerstone for those dedicated to exploring the complexities of viral research.